Who Buys Actinomycin from India — 351 Importers Behind a $2.9M Market
India's actinomycin import market is served by 351 active buyers who collectively imported $2.9M across 933 shipments. EUGIA US LLC (UNITED STATES) leads with a 35.7% market share, followed by EUGIA US LLC, and AUROLOGISTIC LLC. The top 5 buyers together control 75.3% of total import value, reflecting a concentrated buyer landscape.
Top Actinomycin Importers — Ranked by Import Value
EUGIA US LLC (UNITED STATES) is the leading actinomycin importer from India, holding a 35.7% share of the $2.9M market across 933 shipments from 351 buyers. The top 5 buyers — EUGIA US LLC (UNITED STATES), EUGIA US LLC, (UNITED STATES), AUROLOGISTIC LLC (UNITED STATES), ONCOPHARM SPECIALITY PHARMACY (UGANDA), ETHIOPIAN PHARMACEUTICALS (ETHIOPIA) — collectively control 75.3% of total import value.
Top Actinomycin Buyers & Importers
Ranked by import value · 351 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | EUGIA US LLCUNITED STATES DACTINOMYCIN FOR INJECTION 0.5 MG/VIAL )DACILON 0.5 MG DACTINOMYCIN INJDACILON 0.5 DACTINOMYCIN INJ. | $1.0M | 5 | 35.7% |
| 2 | EUGIA US LLC,UNITED STATES DACTINOMYCIN FOR INJECTION 0.5 MG/VIAL )DACILON 0.5 MG DACTINOMYCIN INJDACILON 0.5 DACTINOMYCIN INJ. | $754.4K | 5 | 25.7% |
| 3 | AUROLOGISTIC LLCUNITED STATES | $348.8K | 5 | 11.9% |
| 4 | ONCOPHARM SPECIALITY PHARMACYUGANDA DACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG IDACTINOMYCIN 0.5MG INJ ,PACK-1 VIALVLSCOSMEDAC 0.5MG | $33.2K | 5 | 1.1% |
| 5 | ETHIOPIAN PHARMACEUTICALSETHIOPIA DACTINOMYCIN FOR INJECTION USP 0.5 MG/5MDACTINOVA | $25.4K | 5 | 0.9% |
| 6 | TO THEBRAZIL DACTINOMYCIN FOR INJECTION 0.5 MG/VIAL )DACTINOMYCIN FOR INJECTION USP 0.5 MG/5MDACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG I | $25.0K | 5 | 0.9% |
| 7 | EXP CODEBRAZIL DACTINOMYCIN INJECTION USP 0 5MG VIALDACILON 0.5 MG DACTINOMYCIN USP./0.5MG(BDACILON 0.5 | $10.2K | 5 | 0.3% |
| 8 | TO THE MANAGER-BRAZIL DACTINOMYCIN FOR INJECTION 0.5 MG/VIAL )DACTINOMYCIN FOR INJECTION USP 0.5 MG/5MDACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG I | $8.1K | 5 | 0.3% |
| 9 | TO THE,BRAZIL DACTINOMYCIN FOR INJECTION 0.5 MG/VIAL )DACTINOMYCIN FOR INJECTION USP 0.5 MG/5MDACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG I | $7.9K | 5 | 0.3% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Actinomycin — and from which countries?
Flow of Actinomycin exports from India: each country's share and the named importers behind the numbers
Actinomycin — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $2.2M through 9 shipments. This represents a market share of 73.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• EUGIA US LLC - $1.0M (48.6% of country's total business)
• EUGIA US LLC, - $754.4K (35.0% of country's total business)
• AUROLOGISTIC LLC - $348.8K (16.2% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $239.5K, indicating premium pricing strategy compared to the market average of $3.1K.
United States is a key market for Actinomycin imports, representing 73.5% of total trade value.
2Brazil
Brazil emerges as the second largest importing country, achieving a total trade value of $245.8K through 61 shipments. This represents a market share of 8.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Brazil has a diverse importer base, with their top importers including:
• TO THE - $25.0K (10.2% of country's total business)
• EXP CODE - $10.2K (4.1% of country's total business)
• TO THE MANAGER- - $8.1K (3.3% of country's total business)
• TO THE, - $7.9K (3.2% of country's total business)
Key Insight: Brazil demonstrates strong market positioning with an average shipment value of $4.0K, indicating premium pricing strategy compared to the market average of $3.1K.
Brazil is a key market for Actinomycin imports, representing 8.4% of total trade value.
3Uganda
Uganda emerges as the third largest importing country, achieving a total trade value of $37.6K through 3 shipments. This represents a market share of 1.3% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Uganda has a diverse importer base, with their top importers including:
• ONCOPHARM SPECIALITY PHARMACY - $33.2K (88.5% of country's total business)
Key Insight: Uganda demonstrates strong market positioning with an average shipment value of $12.5K, indicating premium pricing strategy compared to the market average of $3.1K.
Uganda is a key market for Actinomycin imports, representing 1.3% of total trade value.
4Ethiopia
Ethiopia emerges as the fourth largest importing country, achieving a total trade value of $36.0K through 2 shipments. This represents a market share of 1.2% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Ethiopia has a diverse importer base, with their top importers including:
• ETHIOPIAN PHARMACEUTICALS - $25.4K (70.6% of country's total business)
Key Insight: Ethiopia demonstrates strong market positioning with an average shipment value of $18.0K, indicating premium pricing strategy compared to the market average of $3.1K.
Ethiopia is a key market for Actinomycin imports, representing 1.2% of total trade value.
5United Arab Emirates
United Arab Emirates emerges as the fifth largest importing country, achieving a total trade value of $31.3K through 0 shipments. This represents a market share of 1.1% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: United Arab Emirates demonstrates strong market positioning with an average shipment value of $31.3K, indicating premium pricing strategy compared to the market average of $3.1K.
United Arab Emirates is a key market for Actinomycin imports, representing 1.1% of total trade value.
Buyer Segment Analysis
TransData Nexus Actinomycin buyer market intelligence
1Buyer Segment Analysis
The importers of Actinomycin from India can be categorized into several segments:
1. Distributors: Entities like EUGIA US LLC and AUROLOGISTIC LLC in the United States fall into this category. Distributors typically purchase large volumes to supply hospitals, pharmacies, and other healthcare providers. Their buying behavior is characterized by bulk orders and a focus on maintaining a consistent supply chain to meet market demand.
2. Hospital Groups: Organizations such as ONCOPHARM SPECIALITY PHARMACY in Uganda and ETHIOPIAN PHARMACEUTICALS in Ethiopia represent hospital groups. These buyers procure Actinomycin directly for patient treatment within their facilities. Their order patterns are often based on patient needs and treatment protocols, leading to variable purchasing volumes.
3. Government Procurement Agencies: Entities like the Ministry of Health in Ethiopia and the National Medical Stores in Uganda engage in centralized procurement for public healthcare institutions. Their purchasing behavior involves large-scale tenders and contracts to ensure the availability of essential medicines across the public health sector.
4. Re-exporters: Companies such as TO THE and EXP CODE in Brazil may act as re-exporters, purchasing Actinomycin for distribution to neighboring countries. Their buying patterns are influenced by regional demand and trade agreements, often resulting in fluctuating order sizes.
5. Contract Manufacturers: Some buyers may engage in contract manufacturing, sourcing Actinomycin as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement is typically aligned with production schedules and market demand forecasts.
Country-Specific Import Regulations
TransData Nexus Actinomycin buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process for Actinomycin: Importers must ensure that Actinomycin is approved by the FDA. The process involves submitting a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) for generic versions. Additionally, facilities manufacturing the drug must be registered with the FDA and comply with Good Manufacturing Practices (GMP).
3. Estimated Timeline for Registration: The FDA review process for NDAs typically takes 10 months, while ANDAs may take 8 to 10 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under HS code 30049046 are generally duty-free in the United States.
Brazil
1. Drug Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
2. Import Registration Process for Actinomycin: Importers must obtain a sanitary license from ANVISA, register the product, and ensure compliance with Brazilian pharmacopoeia standards. The process includes dossier submission, technical evaluation, and GMP certification of the manufacturing facility.
3. Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and ANVISA's workload.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under this HS code are subject to an import duty of 8% in Brazil.
Uganda
1. Drug Regulatory Authority: National Drug Authority (NDA).
2. Import Registration Process for Actinomycin: Importers must submit an application to the NDA, including product dossiers, GMP certificates, and samples. The NDA conducts evaluations to ensure safety, efficacy, and quality.
3. Estimated Timeline for Registration: The process typically takes 6 to 9 months, subject to the promptness of the applicant's responses to queries.
4. Import Tariff/Duty for HS 30049046: Uganda imposes an import duty of 0% on pharmaceutical products under this HS code, aligning with its policy to promote access to essential medicines.
Ethiopia
1. Drug Regulatory Authority: Ethiopian Food and Drug Authority (EFDA).
2. Import Registration Process for Actinomycin: Importers are required to register the product with the EFDA by submitting a comprehensive dossier, including clinical data, GMP certification, and labeling information.
3. Estimated Timeline for Registration: The registration process can take between 12 to 18 months, depending on the complexity of the product and the EFDA's review capacity.
4. Import Tariff/Duty for HS 30049046: Ethiopia applies an import duty of 5% on pharmaceutical products under this HS code.
United Arab Emirates
1. Drug Regulatory Authority: Ministry of Health and Prevention (MOHAP).
2. Import Registration Process for Actinomycin: Importers must obtain product registration from MOHAP, which involves submitting detailed documentation, including clinical studies, GMP certificates, and product samples.
3. Estimated Timeline for Registration: The registration process typically takes 6 to 12 months, contingent on the completeness of the submission and MOHAP's evaluation schedule.
4. Import Tariff/Duty for HS 30049046: The UAE imposes a 5% import duty on pharmaceutical products under this HS code.
Demand Drivers & Market Opportunity
TransData Nexus Actinomycin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Actinomycin in importing countries is primarily driven by its critical role in treating various cancers, including Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. The inclusion of Actinomycin on the WHO Model List of Essential Medicines underscores its importance in oncology treatment protocols. (who.int)
Government healthcare programs and the expansion of universal health coverage have significantly increased access to essential medicines. For instance, the WHO's efforts to improve global access to essential medicines have led to the regular updating of the WHO Model Lists of Essential Medicines and providing technical support to member states. (who.int) Additionally, tender-based purchasing mechanisms, as recommended by the WHO, have been implemented to ensure the availability and affordability of essential medicines like Actinomycin.
Our data indicates that Actinomycin has been exported to 97 countries, with 351 buyers recorded. The repeat buyer rate of 28.8% suggests a stable demand, likely due to ongoing treatment needs and the drug's established efficacy. This consistent demand presents a substantial market opportunity for suppliers, especially in countries with expanding healthcare infrastructures and commitments to universal health coverage.
Common Questions — Actinomycin Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest actinomycin buyer importing from India?
Based on import volume and value, EUGIA US LLC (UNITED STATES) leads with $1.0M in imports and a 35.7% market share — the highest of any single actinomycin importer. EUGIA US LLC, (UNITED STATES) and AUROLOGISTIC LLC (UNITED STATES) are the next largest buyers.
QHow many companies buy actinomycin from India?
There are 351 active actinomycin buyers importing from India, with a combined market of $2.9M across 933 shipments to 97 countries. The top 5 buyers hold 75.3% of total import value, while the remaining 346 buyers handle the other 24.7%.
QWhich countries import the most actinomycin from India?
The top importing countries for actinomycin from India are United States (73.5%), Brazil (8.4%), Uganda (1.3%), Ethiopia (1.2%), United Arab Emirates (1.1%). These markets represent the largest demand centres for Indian pharmaceutical exports of actinomycin, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for actinomycin from India?
The average import transaction value for actinomycin from India is $3.1K, with an average unit price of $14.44 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Actinomycin buyer market intelligence
1Buyer Segment Analysis
The importers of Actinomycin from India can be categorized into several segments:
1. Distributors: Entities like EUGIA US LLC and AUROLOGISTIC LLC in the United States fall into this category. Distributors typically purchase large volumes to supply hospitals, pharmacies, and other healthcare providers. Their buying behavior is characterized by bulk orders and a focus on maintaining a consistent supply chain to meet market demand.
2. Hospital Groups: Organizations such as ONCOPHARM SPECIALITY PHARMACY in Uganda and ETHIOPIAN PHARMACEUTICALS in Ethiopia represent hospital groups. These buyers procure Actinomycin directly for patient treatment within their facilities. Their order patterns are often based on patient needs and treatment protocols, leading to variable purchasing volumes.
3. Government Procurement Agencies: Entities like the Ministry of Health in Ethiopia and the National Medical Stores in Uganda engage in centralized procurement for public healthcare institutions. Their purchasing behavior involves large-scale tenders and contracts to ensure the availability of essential medicines across the public health sector.
4. Re-exporters: Companies such as TO THE and EXP CODE in Brazil may act as re-exporters, purchasing Actinomycin for distribution to neighboring countries. Their buying patterns are influenced by regional demand and trade agreements, often resulting in fluctuating order sizes.
5. Contract Manufacturers: Some buyers may engage in contract manufacturing, sourcing Actinomycin as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement is typically aligned with production schedules and market demand forecasts.
Country-Specific Import Regulations
TransData Nexus Actinomycin buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process for Actinomycin: Importers must ensure that Actinomycin is approved by the FDA. The process involves submitting a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) for generic versions. Additionally, facilities manufacturing the drug must be registered with the FDA and comply with Good Manufacturing Practices (GMP).
3. Estimated Timeline for Registration: The FDA review process for NDAs typically takes 10 months, while ANDAs may take 8 to 10 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under HS code 30049046 are generally duty-free in the United States.
Brazil
1. Drug Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
2. Import Registration Process for Actinomycin: Importers must obtain a sanitary license from ANVISA, register the product, and ensure compliance with Brazilian pharmacopoeia standards. The process includes dossier submission, technical evaluation, and GMP certification of the manufacturing facility.
3. Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and ANVISA's workload.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under this HS code are subject to an import duty of 8% in Brazil.
Uganda
1. Drug Regulatory Authority: National Drug Authority (NDA).
2. Import Registration Process for Actinomycin: Importers must submit an application to the NDA, including product dossiers, GMP certificates, and samples. The NDA conducts evaluations to ensure safety, efficacy, and quality.
3. Estimated Timeline for Registration: The process typically takes 6 to 9 months, subject to the promptness of the applicant's responses to queries.
4. Import Tariff/Duty for HS 30049046: Uganda imposes an import duty of 0% on pharmaceutical products under this HS code, aligning with its policy to promote access to essential medicines.
Ethiopia
1. Drug Regulatory Authority: Ethiopian Food and Drug Authority (EFDA).
2. Import Registration Process for Actinomycin: Importers are required to register the product with the EFDA by submitting a comprehensive dossier, including clinical data, GMP certification, and labeling information.
3. Estimated Timeline for Registration: The registration process can take between 12 to 18 months, depending on the complexity of the product and the EFDA's review capacity.
4. Import Tariff/Duty for HS 30049046: Ethiopia applies an import duty of 5% on pharmaceutical products under this HS code.
United Arab Emirates
1. Drug Regulatory Authority: Ministry of Health and Prevention (MOHAP).
2. Import Registration Process for Actinomycin: Importers must obtain product registration from MOHAP, which involves submitting detailed documentation, including clinical studies, GMP certificates, and product samples.
3. Estimated Timeline for Registration: The registration process typically takes 6 to 12 months, contingent on the completeness of the submission and MOHAP's evaluation schedule.
4. Import Tariff/Duty for HS 30049046: The UAE imposes a 5% import duty on pharmaceutical products under this HS code.
Demand Drivers & Market Opportunity
TransData Nexus Actinomycin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Actinomycin in importing countries is primarily driven by its critical role in treating various cancers, including Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. The inclusion of Actinomycin on the WHO Model List of Essential Medicines underscores its importance in oncology treatment protocols. (who.int)
Government healthcare programs and the expansion of universal health coverage have significantly increased access to essential medicines. For instance, the WHO's efforts to improve global access to essential medicines have led to the regular updating of the WHO Model Lists of Essential Medicines and providing technical support to member states. (who.int) Additionally, tender-based purchasing mechanisms, as recommended by the WHO, have been implemented to ensure the availability and affordability of essential medicines like Actinomycin.
Our data indicates that Actinomycin has been exported to 97 countries, with 351 buyers recorded. The repeat buyer rate of 28.8% suggests a stable demand, likely due to ongoing treatment needs and the drug's established efficacy. This consistent demand presents a substantial market opportunity for suppliers, especially in countries with expanding healthcare infrastructures and commitments to universal health coverage.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 351 global importers of Actinomycin identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 933 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 97 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
933 Verified Shipments
351 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists